
ARDELYX, INC.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Ardelyx is a biopharmaceutical company that develops medicines to treat cardiorenal and gastrointestinal diseases, including therapies for hyperphosphatemia in dialysis patients and irritable bowel syndrome with constipation.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Reilly Joseph JamesSee Remarks | Sell | $11K | 2,872at $3.86 | Aug 21, 2026 |
| Hohenleitner SusanChief Financial Officer | Sell | $6K | 1,558at $3.86 | Aug 21, 2026 |
| Reilly Joseph JamesSee Remarks | Sell | $4K | 1,110at $3.86 | Aug 21, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ARDX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.